Presented by Prof Dr Sagar Lonial (Winship Cancer Institute, Emory University, Atlanta, GA, USA)
The EXCALIBER-RRMM trial evaluated an iberdomide-based regimen in relapsed/refractory multiple myeloma, with minimal residual disease (MRD) negativity incorporated as a dual primary endpoint. In this video, Prof Dr Sagar Lonial of the Winship Cancer Institute of Emory University summarizes the main results of this trial as presented at the 2026 Annual Meeting of the International Myeloma Society (IMS) in Glasgow.
Iberdomide binds cereblon and was described as more potent and selective than conventional immunomodulatory drugs (IMiDs), with enhanced immune activation and potential for combination with other immunotherapies. The presented randomized trial enrolled more than 800 patients across stages 1 and 2 and compared iberdomide, daratumumab, and dexamethasone with daratumumab, bortezomib, and dexamethasone.
MRD negativity was achieved in approximately 40% of patients in the iberdomide-containing arm compared with 20% in the bortezomib-containing arm. This difference was accompanied by an approximately twofold higher complete remission rate with the iberdomide regimen. From a safety perspective, grade 3–4 neutropenia was increased with iberdomide and was characterized as an expected on-target adverse event. In contrast, non-hematologic toxicities associated with the IMiD class, including fatigue and gastrointestinal toxicity, were lower. Progression-free survival follow-up remains ongoing.
Together, these findings support the use of the iberdomide-based combination in early relapsed multiple myeloma.
Reference:
Lonial S, et al. IMS 2026; Abstract LBA-12